Specifically for the combination therapy, the significantly enriched IPA pathways are FXR/RXR activation, LPS/IL-1–mediated inhibition of RXR function, hepatic cholestasis, NRF2-mediated oxidative stress and glucocorticoid receptor signaling, while for the significantly enriched KEGG pathway they include the renin-angiotensin system, cytokine-cytokine receptor interaction, tryptophan and glutathione metabolism and the Janus kinase/signal transducers and activators of transcription (JAK-STAT) pathway. The gene discussed is REN; the disease is cholestasis.